Should I Buy AVDL? AVDL 2026 Analysis

Should You Buy Avadel Pharmaceuticals PLC (AVDL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

21.690

1 Day change

0.42%

52 Week Range

23.570

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price (21.58 pre-market) is sitting right on the pivot (21.562) and just below nearby resistance (R1 21.623 / R2 21.661), which makes immediate upside look limited versus downside to S1/S2.
Trend is broadly bullish (stacked moving averages), but momentum is cooling (MACD histogram still below zero), suggesting risk of a short-term stall/pullback.
Options tape is mixed-to-cautious near-term (heavy put volume), which is not what you want when buying into resistance.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.
Influential/political activity: no recent congress trading data and no notable insider/hedge fund trend signal provided.

Technical Analysis

Price/levels: 21.58 pre-market is essentially at Pivot 21.562; immediate overhead resistance at 21.623–21.661; supports at 21.501 then 21.463.
Moving averages: bullish structure (SMA_5 > SMA_20 > SMA_200) = primary uptrend intact.
MACD: histogram -0.0131 (below 0) and negatively contracting = bearish momentum is fading, but still not a clean momentum buy signal.
RSI(6): 68.13 = near the upper end of neutral/approaching overbought, consistent with “not much room” before a pause.
Pattern-based forward odds (provided): positive bias (next day +0.57%, week +3.59%, month +7.15%), but near-term entry is technically crowded under resistance.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning (Open Interest): Put/Call OI ratio 0.38 (calls dominate OI) = generally bullish longer positioning.
Flow (Volume): Put/Call volume ratio 3.8 with 1,671 puts vs 440 calls = near-term protection/speculation skewing bearish.
Activity: today’s option volume is ~35.37x the 30-day average, indicating an event/positioning burst despite no news listed.
Volatility: IV 57.91 vs HV 70.55; IV percentile 34 / IV rank 25 = volatility not extreme, but the put-heavy flow near resistance adds caution for an immediate buy.

Technical Summary

Sell

Buy

Positive Catalysts

- Strong top-line growth in the latest reported quarter (2025/Q3): revenue up +54.86% YoY.
- Very high and improving gross margin (93.05%, +6.10% YoY) supports strong unit economics.
- Technical trend backdrop remains constructive (bullish moving average stack).
- If the market is focused on strategic value in the sleep space (as implied by Street commentary around ALKS/AVDL), that can support valuation sentiment even without weekly news.

Neutral/Negative Catalysts

- Profitability deterioration: 2025/Q3 net income fell to ~0.02M (down -100.76% YoY) and EPS to 0 (down -100% YoY), which can cap multiple expansion.
- No fresh news catalysts in the last week to drive a clean breakout through nearby resistance.
- Options flow is defensively skewed (put volume dominance) and unusually elevated, which often precedes choppy/mean-reverting price action short term.
- Hedge funds/insiders: neutral trends (no supportive accumulation signal indicated).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 77.47M, +54.86% YoY (strong growth trend).
Gross margin: 93.05%, +6.10% YoY (excellent margin profile).
Net income: 0.02M, -100.76% YoY (sharp deterioration).
EPS: 0, -100.00% YoY (profitability not currently translating to per-share earnings).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent Street actions (provided):
- 2025-11-20: Wells Fargo raised PT to $22.50 from $20, kept Equal Weight (cautious/neutral stance despite higher PT).
- 2025-11-11: Truist initiated ALKS with Buy and discussed ALKS’s acquisition of AVDL strategically (supportive read-through for AVDL’s strategic value).
Trend summary: modestly improving price targets/strategic narrative, but not a clear wave of “Buy” upgrades on AVDL itself.
Wall Street pros: strategic asset value in sleep/narcolepsy space; improving PT; strong revenue growth.
Wall Street cons: core rating tone remains neutral (Equal Weight), and profitability metrics have weakened materially, limiting aggressive upside calls.

10 Analyst Rating

Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 20.29 USD with a low forecast of 18.5 USD and a high forecast of 22.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

10 Hold

0 Sell

Hold

Current: 21.600

Low

18.5

Averages

20.29

High

22.5

Current: 21.600

Low

18.5

Averages

20.29

High

22.5

Wells Fargo

Equal Weight

maintain

$20

AI Analysis

2025-11-20

Reason

Wells Fargo

Price Target

$20

AI Analysis

2025-11-20

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $20 and keeps an Equal Weight rating on the shares. The firm says updated Alkermes' (ALKS) offer looks better to Wells, with a similar upfront but better CVR terms that it thinks are likely to pay out.

Truist

initiated

$50

2025-11-11

Reason

Truist

Price Target

$50

2025-11-11

initiated

Reason

Truist initiated coverage of Alkermes (ALKS) with a Buy rating and $50 price target. The firm values the base business and cash at about $29 per share, which it sees "setting a high floor" heading into Phase 2 Vibrance-2 data in narcolepsy type 2. Narcolepsy type 1 alone is worth $8 per share in the firm's sum-of-the-parts valuation, while NT2 and idiopathic hypersomnia contribute $8 per share and $5 per share, respectively, the analyst tells investors. Alkermes "doubling down" in sleep space with the acquisition of Avadel (AVDL) is a strategic move that gives it a first-mover advantage over Takeda (TAK), the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AVDL

Unlock Now

AVDL Should I Buy

AVDL Should I Buy

Should You Buy Avadel Pharmaceuticals PLC (AVDL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch